Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. - Test2 - elhamkhani - TriplyDB

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

http://www.wikidata.org/entity/Q33750580

about

Anti-androgenic effects of flavonols in prostate cancer Molecular cancer prevention: Current status and future directions Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity.Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic Use of administrative data to increase the practicality of clinical trials: Insights from the Women's Health Initiative.Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial Intraoperative floppy iris syndrome: pathophysiology, prevention, and treatment Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217)5-α reductase inhibitors and prostate cancer prevention: where do we turn now?Long-term survival of participants in the prostate cancer prevention trial.A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).Chemoprevention of prostate cancer.Prevention and early detection of prostate cancer.Models of carcinogenesis: an overview.Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.Prevention of prostate cancer: outcomes of clinical trials and future opportunities.Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer--evidence of effect modification by prostate size Health-related quality-of-life findings for the prostate cancer prevention trial Current status of 5α-reductase inhibitors in prostate disease management Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.Finasteride in the treatment of patients with benign prostatic hyperplasia: a review Future directions in the prevention of prostate cancer.High-grade prostate cancer and finasteride.Finasteride.Should prostate-specific antigen screening be offered to asymptomatic men?Prevention strategies in prostate cancer.Testosterone replacement and prostate cancer.Hair restoration surgery: the state of the art.Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges.An introduction to acinar pressures in BPH and prostate cancer.

P2860

Q26777700-D32327D8-2D89-4B26-9FB3-346D1EC86300 Q26797207-73057E5A-9EF4-4689-B1E3-5A096FDFA616 Q28534518-E90DDFFD-2EF9-4726-98FD-2BBBADBD7EEF Q29619860-003DC479-AFD8-4BD1-A4E0-660CC8EBE12C Q30362087-177ACAFD-0F79-4AA8-BBD5-D2735C8C26BA Q30498812-516F4D81-8138-423B-BAC2-7980FC366417 Q31111666-DCD24D8F-6FAA-4D09-A880-7D41A7DF18AE Q33356928-A3769A41-1E2A-4B72-B53F-73DAB7C00F46 Q33532998-85F539B2-6754-48A2-BF85-383E234ACA11 Q33623451-CB9E5DF8-2C61-4DB4-9F73-E88A17167FF9 Q33756403-5CEB8264-7E6D-42A3-9667-150C3511CA3D Q33823702-3B8B7E42-3261-462E-830A-ED31EEFBC695 Q33992410-C8816712-1056-43DE-B18E-A6D8A23DC93C Q34020127-B69FFC58-75FD-4D1F-A492-2790855CE3CE Q34077860-171C7674-E83F-4BEB-897C-2C4096C18F82 Q34141355-A4527FD5-90BE-4BAC-8145-B9104DEE53BC Q34186757-FEBA801B-AC2A-41D0-8FAD-28A55C7A262C Q34371057-0679B14C-9846-4977-865D-8B478788F671 Q34514709-49F8982A-4216-4C1D-8688-6CEFD6FFCAD8 Q34604979-E09C346B-15E5-410F-93E7-113AF8BF1375 Q34682926-99C6FB0A-0989-4D34-B5A4-ECCE48D94A7B Q35067699-66F9AD4C-5EA2-4550-BBB4-9F71A63B3A20 Q35111934-DF171F39-123A-4620-9D4D-2FD9F7A39481 Q36306367-D2C38479-9E78-4633-B1FE-A07D9A9684A8 Q36413132-C8BA5315-DFB9-4DA1-AB5B-5386875B7C62 Q36442301-D2386E21-DC96-45F2-BD0C-17AD267062E1 Q36486786-3A2FD94D-BA84-48D8-AF85-7F8C91EF1631 Q36778346-404273B4-41DF-4BA6-976F-15552FBBD740 Q36883768-C1821416-9B84-474E-AAC3-F1292F9873F2 Q36937301-F9DA878F-446D-4A8E-96BF-ED5722735B81 Q37261063-95CA9574-4EFD-49A8-BF57-9368D4C7FFBB Q37279094-6FB8AE32-325E-4784-A26D-4C49FDD2B3A4 Q37636370-A67B0084-1283-48AB-B94D-9C252600C6DB Q37763952-A3F4C819-C076-485A-AC19-BC76BDF8A34A Q37774352-ECF84928-390B-41FA-A439-DD1D6EF5155A Q37794799-898FBAFC-4FD9-4E06-8D72-417E1CEF3ADE Q38037508-EE0B9E71-7F87-49BA-9E0C-C940B9E03C60 Q38061405-BE10EBF0-9280-4383-BD36-3BEB01A642F5 Q38092015-AD802EDC-C9A9-4B2E-AC4F-BC00A1BA391B Q38106624-F0DCB3EB-E14C-4CDF-9F8C-B50D576E045B

P2860

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

http://www.wikidata.org/entity/Q33750580

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Finasteride does not increase ...... as-adjusted modeling approach.

@ast

Finasteride does not increase ...... as-adjusted modeling approach.

@en

type

label

Finasteride does not increase ...... as-adjusted modeling approach.

@ast

Finasteride does not increase ...... as-adjusted modeling approach.

@en

prefLabel

Finasteride does not increase ...... as-adjusted modeling approach.

@ast

Finasteride does not increase ...... as-adjusted modeling approach.

@en

P1433

Q33750580-B08C1CF3-73E6-454D-85D1-E94D2A61996C

P1476

Q33750580-B25E0FE1-3264-442B-B950-67FE72AEBC8B

P2093

Q33750580-2E5C3F2E-6D40-440C-9E9B-8E7515386498

Q33750580-51B4A9CE-2A2D-41DF-A8E0-0E1DEABE398A

Q33750580-70FD6A74-3B01-4576-9FDA-7B3D44F70412

Q33750580-76F86540-135C-4598-BFC4-D175102AF40B

Q33750580-C844F291-FBFB-40F3-A6D5-C58BF95FCB29

Q33750580-D28096A5-1CB9-42FB-95CE-3BD80BC1C894

P2860

Q33750580-18F7778F-E843-4248-BA86-DB432B62FA21

Q33750580-2529C583-757F-458C-B153-D0B682328780

Q33750580-3C50FCF5-9075-400F-9A89-1CEF7239ECAF

Q33750580-402B6239-0D11-4FD0-A145-AAAFB945B346

Q33750580-83BBA455-670A-496D-8701-74322ED22FFC

Q33750580-86387B2D-F8F5-4902-8DBC-F52A91F106F0

Q33750580-89F18A96-D7F1-423F-BDD8-A21DC5A26AD4

Q33750580-B292CE20-55DA-4DFE-A011-D1A83C9CD38A

Q33750580-C310B77C-0B0E-4AAB-9A42-4AD998F0A922

Q33750580-C3756041-E5E7-4288-B780-04CE00970ED6

P304

Q33750580-ABC76884-8A24-458F-A3D5-37ED7986A822

P31

Q33750580-E848A290-C6E4-4998-AD25-B09660652B63

P356

Q33750580-D2791CEC-3156-44BF-A99E-70797DB95E75

P433

Q33750580-D7152F70-AB14-4529-994B-0FC6ACEF25AF

P478

Q33750580-87EDB694-7ADC-4642-8E37-A9DFEAFB169D

P577

Q33750580-8AEC2810-BC58-4D13-8FE6-D8B8F251B081

P698

Q33750580-7ACADE2D-307F-4B0B-9D46-8C69B54A4020

P921

Q33750580-7DB9E579-2BA6-464E-A981-834F929738BC

P932

Q33750580-F92B15EB-F419-4AF6-9CFB-40E7E9E6ECA0

P356

1940-6207.CAPR-08-0092

P1433

Cancer Prevention Research

P1476

Finasteride does not increase ...... as-adjusted modeling approach.

@en

P2093

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Charles A Coltman

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

M Scott Lucia

http://www.w3.org/2001/XMLSchema#string

Mary W Redman

http://www.w3.org/2001/XMLSchema#string

Phyllis J Goodman

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2007

The influence of finasteride on the development of prostate cancer.

Logistic regression when the outcome is measured with uncertainty.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.

The prostate cancer prevention trial: design, biases and interpretation of study results.

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.

The prevention of prostate cancer--the dilemma continues.

Implementation of the Prostate Cancer Prevention Trial (PCPT).

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

P304

174-181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-08-0092

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19138953

http://www.w3.org/2001/XMLSchema#string

P921

P932

2844801

http://www.w3.org/2001/XMLSchema#string